PureTech Health (LON:PRTC) Trading 14.2% Higher - Here's What Happened

Key Points

• PureTech Health's shares rose by 14.2% on Saturday, closing at GBX 121.50 ($1.64) after reaching a high of GBX 123.80 ($1.67), with trading volume surging 1,053% above average.
• The company has a debt-to-equity ratio of 45.82 and a market cap of £293.65 million, indicating a high valuation with a PE ratio of 714.71.
• Insider Bharatt Chowrira purchased 167,739 shares at GBX 1 each, while insiders overall hold 13.13% of the company's stock.

Shares of PureTech Health plc (LON:PRTC - Get Free Report) rose 14.2% during mid-day trading on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares traded hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Trading Up 4.2%

The company has a market capitalization of £303.07 million, a PE ratio of 737.65 and a beta of 1.02. The company's fifty day moving average is GBX 129.31 and its 200-day moving average is GBX 129.65. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51.

Insider Transactions at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the business's stock in a transaction on Thursday, July 3rd. The shares were acquired at an average cost of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is currently owned by insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.